During the past decade, Women's Cancer Care conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 7 clinical trials were completed, i.e. on average, 43.8% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 4 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Women's Cancer Care" #1 sponsor was "National Cancer Institute (NCI)" with 6 trials, followed by "ImmunoGen, Inc." with 3 trials sponsored, "AEterna Zentaris" with 1 trials sponsored, "Aravive, Inc." with 1 trials sponsored and "Astex Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Women's Cancer Care" #1 collaborator was "NRG Oncology" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Canadian Cancer Trials Group" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Women's Cancer Care" are "Ovarian Cancer" (6 trials), "Fallopian Tube Cancer" (5 trials), "Recurrent Ovarian Carcinoma" (4 trials), "Epithelial Ovarian Cancer" (3 trials) and "Fallopian Tube Clear Cell Adenocarcinoma" (3 trials). Many other conditions were trialed in "Women's Cancer Care" in a lesser frequency.

Most popular intervention types in "Women's Cancer Care" are "Drug" (18 trials), "Other" (7 trials), "Biological" (5 trials), "Procedure" (5 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (6 trials), "Quality-of-Life Assessment" (4 trials), "Carboplatin" (3 trials), "Cediranib Maleate" (3 trials) and "Computed Tomography" (3 trials). Other intervention names were less common.

The vast majority of trials in "Women's Cancer Care" are 18 trials for "Female" genders and 5 trials for "All" genders.

Currently, there are NaN active trials in "Women's Cancer Care". undefined are not yet recruiting, 4 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Women's Cancer Care, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Women's Cancer Care, 2 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".